572px-Sysmex_company_logo.svg
  • Products & Services
    • BioPharma Testing
    • Clinical Testing
    • SafeSEQ Tests
    • Custom SafeSEQ
    • OncoBEAM Tests
    • Kit Products (Ex-US)
  • Science & Technology
    • SafeSEQ Technology
    • OncoBEAM Technology
    • ctDNA Analysis Advantages
    • Publications
  • Blog
  • Company
    • Latest News & Press Releases
    • About Us
    • Careers
    • The Sysmex Way
    • Lab Certificates
    • Contact
  • Products & Services
    • BioPharma Testing
    • Clinical Testing
    • SafeSEQ Tests
    • Custom SafeSEQ
    • OncoBEAM Tests
    • Kit Products (Ex-US)
  • Science & Technology
    • SafeSEQ Technology
    • OncoBEAM Technology
    • ctDNA Analysis Advantages
    • Publications
  • Blog
  • Company
    • Latest News & Press Releases
    • About Us
    • Careers
    • The Sysmex Way
    • Lab Certificates
    • Contact
Menu
  • Products & Services
    • BioPharma Testing
    • Clinical Testing
    • SafeSEQ Tests
    • Custom SafeSEQ
    • OncoBEAM Tests
    • Kit Products (Ex-US)
  • Science & Technology
    • SafeSEQ Technology
    • OncoBEAM Technology
    • ctDNA Analysis Advantages
    • Publications
  • Blog
  • Company
    • Latest News & Press Releases
    • About Us
    • Careers
    • The Sysmex Way
    • Lab Certificates
    • Contact

Sysmex Inostics

All stories by Sysmex

Other Authors

  • Dale Yuzuki (1)
  • Sysmex (1)
  • Sysmex Inostics (13)
pre-analytics

Sysmex Inostics Presents Data Demonstrating Exquisite Sensitivity of SafeSEQ NGS Detection of MRD AML at ASH Annual Meeting

Dec 8, 2020 12:57:40 PM |
3 min read
Press Release

Sysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management

Sep 8, 2020 6:00:00 AM |
2 min read
Press Release

Sysmex Inostics’ OncoBEAM™ RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy

Aug 27, 2020 6:00:00 AM |
2 min read
Press Release

Sysmex Inostics’ Colorectal Cancer Blood-Based OncoBEAM™ RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing

Aug 5, 2020 6:00:40 AM |
3 min read
Press Release

Sysmex Inostics and Oxford Gene Technology plasma and tissue sequencing demonstrate clearance of ctDNA correlates w/ pathologic complete response in breast cancer patients during neoadjuvant treatment

Jan 28, 2020 6:15:00 AM |
2 min read
Press Release

Sysmex Inostics Tissue-independent Liquid Biopsy for Early Stage Breast Cancer Mutation Characterization and Monitoring Using Ultra-sensitive SafeSEQ Technology

Dec 16, 2019 6:44:37 AM |
3 min read
Press Release

Sysmex Inostics launches two NGS-based liquid biopsy panels for cancer therapy drug development

Sep 27, 2019 6:05:00 AM |
3 min read
Press Release

Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging

Sep 4, 2019 6:30:46 AM |
2 min read
Press Release

Sysmex obtains Japanese manufacturing and marketing approval for the first blood-based RAS mutation testing for colorectal cancer

Aug 2, 2019 8:20:26 AM |
2 min read
Germany

Sysmex Inostics OncoBEAM™-EGFR Digital PCR Liquid Biopsy Demonstrates Two-fold Higher Detection of p.T790M Mutations in 183 NSCLC Patients in Comparison Study

May 30, 2019 1:51:00 PM |
2 min read

|
1 min read

|
1 min read
See More

  • Company
    • Latest News & Press Releases
    • Blog
    • Lab Certificates

Information in accordance with Art. 13 GDPR: https://www.sysmex-inostics.com/data


Sysmex logo

Germany: Sysmex Inostics GmbH, Falkenried 88, D-20251 Hamburg, Germany. +49 40- 325907-0

United States: Sysmex Inostics, Inc., 1812 Ashland Ave Suite 500, Baltimore, Maryland 21205, USA.   +1-855-BEAM-DNA (232-6362)

Japan: Sysmex Corporation, 1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan.   +81 78 265-0500

Copyright © Sysmex Inostics, All Rights Reserved.